TransMedics Group (NASDAQ:TMDX) Reaches New 1-Year Low on Insider Selling

TransMedics Group, Inc. (NASDAQ:TMDX)’s stock price reached a new 52-week low during mid-day trading on Thursday after an insider sold shares in the company. The company traded as low as $68.80 and last traded at $69.10, with a volume of 631739 shares trading hands. The stock had previously closed at $72.21.

Specifically, insider Tamer I. Khayal sold 1,084 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the sale, the insider now owns 20,843 shares in the company, valued at $1,800,835.20. This trade represents a 4.94 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TMDX. Oppenheimer reissued an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a report on Tuesday. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research report on Tuesday. JPMorgan Chase & Co. decreased their price objective on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 29th. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Finally, Robert W. Baird reduced their target price on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, October 29th. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $131.80.

TransMedics Group Stock Down 8.3 %

The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company has a fifty day moving average price of $105.43 and a 200 day moving average price of $134.42. The company has a market cap of $2.22 billion, a PE ratio of 70.48 and a beta of 2.06.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The company had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business’s revenue was up 63.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.12) earnings per share. As a group, analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

Hedge Funds Weigh In On TransMedics Group

Hedge funds and other institutional investors have recently modified their holdings of the company. Wilmington Savings Fund Society FSB purchased a new position in TransMedics Group in the 3rd quarter worth approximately $149,000. Sanctuary Advisors LLC increased its stake in shares of TransMedics Group by 63.4% in the third quarter. Sanctuary Advisors LLC now owns 4,041 shares of the company’s stock worth $634,000 after buying an additional 1,568 shares during the period. Morse Asset Management Inc purchased a new position in shares of TransMedics Group in the third quarter worth $823,000. Virtu Financial LLC bought a new stake in TransMedics Group during the 3rd quarter valued at $436,000. Finally, Neo Ivy Capital Management purchased a new stake in TransMedics Group during the 3rd quarter valued at $554,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.